Accelerate to discover
Related topics
Discover the newly re-designed TissueGnostics portfolio
Sep 18, 2020
TissueGnostics is a solution provider for Precision Medicine and provides fully integrated cutting-edge tissue...
Imaging Performance of a multimodal module to enhance preclinical irradiator capabilities
Sep 15, 2020
Upgrading an existing irradiator with such a multi-modal imaging device is a reasonable investment in laboratories...
Get more out of your full spectrum panel with Cytek’s new reagent family
Aug 17, 2020
Cytek Biosciences has already redefined what is possible in flow cytometry. The new Cytek cFluor family of reagents...
Introducing Amnis AI Image Analysis software
Aug 4, 2020
Amnis AI Image Analysis Software combines the power of high dimensional data reduction with artificial intelligence,...
The Role of Micro-CT in Imaging Breast Cancer Specimens
Jun 17, 2020
The goal of breast cancer surgery is to remove all of the cancer with a minimum of normal tissue, but absence of full...
Cytek Northern Lights: 41 parameters with 3 lasers only
Jun 12, 2020
Cytek Biosciences Northern Lights incorporates the same innovations as the Aurora, but at a lower price point. It...
Bruker´s micro-CT used for some of the World’s First in vivo COVID-19 Imaging Experiments
Jun 9, 2020
Bruker's BioSpin PreClinical Imaging Division reports the use of the Bruker SkyScan 1278 in vivo micro-CT system at the...
A mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection
Jun 3, 2020
Soft tissue sarcomas pose a significant clinical challenge, with approximately 12,000 new diagnoses and an estimated...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
